Stock News

Genomic Health (GHDX) Shareholder Emory University Raised Stake; Globant S A (GLOB) Stake Held by Sloane Robinson Llp

Globant S.A. (NYSE:GLOB) Logo

Emory University increased its stake in Genomic Health Inc (GHDX) by 17.75% based on its latest 2017Q4 regulatory filing with the SEC. Emory University bought 9,487 shares as the company’s stock declined 13.76% with the market. The institutional investor held 62,926 shares of the health care company at the end of 2017Q4, valued at $2.15M, up from 53,439 at the end of the previous reported quarter. Emory University who had been investing in Genomic Health Inc for a number of months, seems to be bullish on the $1.36B market cap company. The stock decreased 0.26% or $0.1 during the last trading session, reaching $38.35. About 137,213 shares traded. Genomic Health, Inc. (NASDAQ:GHDX) has declined 2.07% since May 23, 2017 and is downtrending. It has underperformed by 13.62% the S&P500.

Hugh Sloane increased its stake in Globant S A (GLOB) by 2.63% based on its latest 2017Q4 regulatory filing with the SEC. Sloane Robinson Llp bought 11,800 shares as the company’s stock rose 14.76% while stock markets declined. The hedge fund run by Hugh Sloane held 459,822 shares of the edp services company at the end of 2017Q4, valued at $21.36 million, up from 448,022 at the end of the previous reported quarter. Sloane Robinson Llp who had been investing in Globant S A for a number of months, seems to be bullish on the $1.79 billion market cap company. The stock decreased 0.93% or $0.47 during the last trading session, reaching $50. About 159,135 shares traded. Globant S.A. (NYSE:GLOB) has risen 42.58% since May 23, 2017 and is uptrending. It has outperformed by 31.03% the S&P500.

More recent Genomic Health, Inc. (NASDAQ:GHDX) news were published by: Seekingalpha.com which released: “Genomic Health’s (GHDX) CEO Kimberly Popovits on Q1 2018 Results – Earnings Call Transcript” on May 03, 2018. Also Benzinga.com published the news titled: “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again” on May 11, 2018. Prnewswire.com‘s news article titled: “Genomic Health to Present at Bank of America Merrill Lynch 2018 Health Care Conference” with publication date: May 09, 2018 was also an interesting one.

Investors sentiment decreased to 1.13 in 2017 Q4. Its down 1.19, from 2.32 in 2017Q3. It dived, as 18 investors sold GHDX shares while 35 reduced holdings. 18 funds opened positions while 42 raised stakes. 31.21 million shares or 1.14% more from 30.86 million shares in 2017Q3 were reported. Cornerstone Cap Management Hldg Limited Liability Co invested in 0.01% or 27,437 shares. First Retail Bank Of Omaha has 0.06% invested in Genomic Health, Inc. (NASDAQ:GHDX) for 30,105 shares. Moreover, Alliancebernstein Limited Partnership has 0% invested in Genomic Health, Inc. (NASDAQ:GHDX) for 37,885 shares. Raymond James And Associates accumulated 13,877 shares. Dubuque Commercial Bank And Tru Commerce holds 5,069 shares or 0.03% of its portfolio. State Farm Mutual Automobile Ins invested in 350,741 shares or 0.02% of the stock. Vanguard Group Incorporated reported 0% in Genomic Health, Inc. (NASDAQ:GHDX). Scout Invs Inc holds 0.06% or 73,450 shares. Tiaa Cref Limited Com accumulated 49,328 shares. Oppenheimer Inc invested in 0.06% or 71,626 shares. Numeric Investors Limited Liability Company reported 0.05% in Genomic Health, Inc. (NASDAQ:GHDX). Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% of its portfolio in Genomic Health, Inc. (NASDAQ:GHDX) for 1,263 shares. Sei holds 0% of its portfolio in Genomic Health, Inc. (NASDAQ:GHDX) for 261 shares. Tower Research Cap Ltd Llc (Trc) has invested 0% in Genomic Health, Inc. (NASDAQ:GHDX). American Group Inc reported 13,305 shares.

Among 11 analysts covering Genomic Health (NASDAQ:GHDX), 2 have Buy rating, 3 Sell and 6 Hold. Therefore 18% are positive. Genomic Health had 34 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Tuesday, September 12 by Jefferies. The stock of Genomic Health, Inc. (NASDAQ:GHDX) earned “Market Perform” rating by Raymond James on Friday, August 28. UBS upgraded Genomic Health, Inc. (NASDAQ:GHDX) on Monday, November 23 to “Buy” rating. Jefferies maintained the shares of GHDX in report on Friday, October 20 with “Hold” rating. The firm has “Hold” rating by William Blair given on Wednesday, December 20. The stock has “Neutral” rating by Piper Jaffray on Monday, January 11. The firm has “Buy” rating given on Wednesday, November 15 by Canaccord Genuity. The firm has “Outperform” rating given on Wednesday, November 4 by Raymond James. The company was maintained on Thursday, May 3 by Deutsche Bank. As per Thursday, August 6, the company rating was downgraded by Zacks.

Since December 12, 2017, it had 0 buys, and 17 selling transactions for $4.53 million activity. The insider Febbo Phillip G. sold 4,942 shares worth $162,290. Shares for $164,014 were sold by Cole G Bradley on Tuesday, March 13. On Wednesday, May 2 Vaughn James J sold $48,653 worth of Genomic Health, Inc. (NASDAQ:GHDX) or 1,497 shares. 21,000 shares valued at $699,000 were sold by Leber Laura on Thursday, December 14. Another trade for 5,500 shares valued at $201,543 was sold by Shak Steven.

Emory University, which manages about $116.54 million US Long portfolio, decreased its stake in Global Blood Therapeutics In by 10,716 shares to 45,441 shares, valued at $1.79 million in 2017Q4, according to the filing. It also reduced its holding in Puma Biotechnology Inc (NYSE:PBYI) by 3,511 shares in the quarter, leaving it with 17,044 shares, and cut its stake in Wave Life Sciences Ltd.

Sloane Robinson Llp, which manages about $250.17 million US Long portfolio, decreased its stake in Grupo Supervielle S A by 100,500 shares to 293,700 shares, valued at $8.61 million in 2017Q4, according to the filing. It also reduced its holding in Taiwan Semiconductor Mfg Ltd (NYSE:TSM) by 119,400 shares in the quarter, leaving it with 61,800 shares, and cut its stake in Banco Macro (NYSE:BMA).

More news for Globant S.A. (NYSE:GLOB) were recently published by: Profitconfidential.com, which released: “GLOB Stock: Soaring High on Digital Services” on May 17, 2018. Seekingalpha.com‘s article titled: “Globant’s (GLOB) CEO Martin Migoya on Q1 2018 Results – Earnings Call Transcript” and published on May 13, 2018 is yet another important article.

Investors sentiment increased to 1.23 in 2017 Q4. Its up 0.21, from 1.02 in 2017Q3. It improved, as 10 investors sold GLOB shares while 25 reduced holdings. 15 funds opened positions while 28 raised stakes. 21.90 million shares or 0.88% less from 22.09 million shares in 2017Q3 were reported. Dimensional Fund Limited Partnership holds 0% of its portfolio in Globant S.A. (NYSE:GLOB) for 140,924 shares. Bancorporation Of America De has invested 0% in Globant S.A. (NYSE:GLOB). Gluskin Sheff & reported 436,634 shares. Morgan Stanley has invested 0.04% of its portfolio in Globant S.A. (NYSE:GLOB). Atlantic Gp Ltd Liability holds 0% of its portfolio in Globant S.A. (NYSE:GLOB) for 32 shares. Citigroup invested 0% in Globant S.A. (NYSE:GLOB). Huntington Bancshares has 1,108 shares for 0% of their portfolio. Cap Invsts stated it has 0.03% in Globant S.A. (NYSE:GLOB). X Lc invested 0.14% in Globant S.A. (NYSE:GLOB). Fil Limited has 93,470 shares. Financial Bank Of Ny Mellon reported 0% of its portfolio in Globant S.A. (NYSE:GLOB). Northern Trust holds 0% of its portfolio in Globant S.A. (NYSE:GLOB) for 80,881 shares. Invesco Ltd holds 0% or 290,242 shares in its portfolio. Fred Alger Incorporated reported 0.1% of its portfolio in Globant S.A. (NYSE:GLOB). Capital Inc reported 11,480 shares or 0.03% of all its holdings.

Among 11 analysts covering Globant SA (NYSE:GLOB), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Globant SA had 28 analyst reports since July 27, 2015 according to SRatingsIntel. The stock of Globant S.A. (NYSE:GLOB) earned “Outperform” rating by Wedbush on Friday, September 9. Citigroup upgraded Globant S.A. (NYSE:GLOB) on Monday, February 8 to “Buy” rating. The firm has “Hold” rating by SunTrust given on Thursday, July 27. On Wednesday, August 12 the stock rating was initiated by Jefferies with “Hold”. The rating was downgraded by KeyBanc Capital Markets to “Sector Weight” on Friday, July 7. The company was upgraded on Wednesday, April 4 by SunTrust. On Friday, January 26 the stock rating was maintained by Cowen & Co with “Buy”. The stock has “Hold” rating by SunTrust on Friday, October 20. The stock has “Hold” rating by Jefferies on Monday, May 16. On Thursday, January 12 the stock rating was upgraded by Pacific Crest to “Overweight”.

Genomic Health, Inc. (NASDAQ:GHDX) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *